• In the context of cancer, appropriately activated DCs can induce anti-tumor immunity by activating innate immune cells and tumor-specific lymphocytes that target cancer cells. (mdpi.com)
  • In hematological malignancies, tumor-derived EVs might reprogram the bone marrow environment, suppress antileukemic immunity, mediate drug resistance and interfere with immunotherapies. (nature.com)
  • EVs collected from the serum of leukemic samples might correlate with disease stage, drug-/immunological resistance, or might correlate with antileukemic immunity/immune response. (nature.com)
  • Metabolic reprogramming plays an important role in tumor progression and antitumor immunity. (medsci.org)
  • Alexandra Gabriela Barros Ferreira defends her Ph.D. thesis "Restoring antitumor immunity with dendritic cell reprogramming strategies" on Friday, 17 November, 2023. (lu.se)
  • My Ph.D. studies have focused on restoring anti-tumor immunity with dendritic cell reprogramming strategies. (lu.se)
  • In line, B cells are closely associated with CD8 + cytotoxic T cells, which are important in antigen-specific immunity against tumors. (medjouel.com)
  • In addition, B cells present tumor-specific antigens via MHCI and MHCII to T cells inducing their anti-tumor effector function. (medjouel.com)
  • Dendritic cells (DCs) are specialized antigen-presenting cells that have a notable role in the initiation and regulation of innate and adaptive immune responses. (mdpi.com)
  • Moreover, any tumor cells that do manage to evade the initial antitumor immune response are mopped up after a second-line virus-based immunotherapy comprising a different set of antigens. (genengnews.com)
  • Recent advances in cancer immunology, highlighted by immune checkpoint inhibitors, have demonstrated that immunotherapy is a viable option in the oncologist's armamentarium. (ndltd.org)
  • This mechanistically rational antigen selection sequence, effective even for unvaccinated donors, regardless of HLA-haplotype, enables rapid identification of tumor protein regions relevant for cancer immunology, including adoptive immunotherapy, vaccines, and even identification of tumor neo-antigens unique to each patient. (ndltd.org)
  • So far, the most successful passive immunotherapy directed to VEGF is Bevacizumab, a monoclonal antibody that neutralizes the binding of VEGF to its receptors [5], which has been approved, in combination with chemotherapy, for the treatment of different tumors [6-12]. (researchsquare.com)
  • In recent years, immunotherapy to activate anti-cancer host immune cells to kill tumors has become a new area of research for the treatment of prostate cancer. (asmepress.com)
  • As an important component of immunotherapy, cancer vaccines have a unique position in the precise treatment of malignant tumors. (asmepress.com)
  • In the past decades, immunotherapy has been used to treat prostate cancer through anti-tumor effects driven by immune response. (asmepress.com)
  • Sipuleucel-T (Provenge®, Dendreon, USA) is an active immune cell-based immunotherapy that induces an immune response against prostate acid phosphatase (PAP). (asmepress.com)
  • Furthermore, similar to T cells, specific recognition and elimination of cancer cells by NK cells can be markedly enhanced through expression of chimeric antigen receptors (CARs), which provides an opportunity to generate NK-cell therapeutics of defined specificity for cancer immunotherapy. (frontiersin.org)
  • Immunotherapy can fail in patients with cancer when certain cancer cells can hide from the immune system. (lu.se)
  • However, cDC1 can be compromised in cancer patients and some cancer cells lack these antigen-presenting proteins on their surface, impacting immunotherapy response. (lu.se)
  • The company is hoping BNT111, which used a fixed combination of mRNA-encoded, tumor-associated antigens to target the cancer cells, will demonstrate the same kind of success as the COVID-19 vaccine. (biospace.com)
  • The SQZ AAC platform is designed to induce antigen presentation in vivo by deriving antigen carriers from engineering red blood cells (RBCs) with tumor specific antigens and adjuvants. (stockhouse.com)
  • Little is known about the antigens expressed in nascent tumour cells, whether they are sufficient to induce protective antitumour immune responses or whether their expression is modulated by the immune system. (nih.gov)
  • Here, using massively parallel sequencing, we characterize expressed mutations in highly immunogenic methylcholanthrene-induced sarcomas derived from immunodeficient Rag2(-/-) mice that phenotypically resemble nascent primary tumour cells. (nih.gov)
  • These results demonstrate that the strong immunogenicity of an unedited tumour can be ascribed to expression of highly antigenic mutant proteins and show that outgrowth of tumour cells that lack these strong antigens via a T-cell-dependent immunoselection process represents one mechanism of cancer immunoediting. (nih.gov)
  • The team's previous work had already shown that killing normal cells in situ using the adjuvant hsp70 generated T cell responses to antigens that mediated rejection of tumors of the same histological type. (genengnews.com)
  • In this ESCA study, the possibility of an immune response that selected for tumor cells lacking the DDX53 CTA is discussed. (biotechnews.com.au)
  • To better understand the potential positive and negative impacts of T-cells in ESCA, we recovered TCR recombination reads from the TCGA-ESCA whole exome sequence (WXS) files, obtained the TCR CDR3 AA sequences, and assessed the chemical complementarity of those sequences with CTAs, as those antigens have been characterized by many approaches over decades as candidate cancer antigens. (biotechnews.com.au)
  • These data and analyses raise the question of whether or not the TCR CDR3-DDX53 chemical complementarity assessment detected an ESCA immune response that selected for DDX53-negative cells. (biotechnews.com.au)
  • The main target and effector cells of the CTLA-4 blockade treatment in the studied tumor models are tumor-specific endogenous CD8 + T cells that are capable of eradicating also distant tumors, whereas CD4 + T cells do not play a prominent role in the antibody-mediated tumor eradication. (aacrjournals.org)
  • The innate immune system includes macrophages, dendritic cells (DC), and natural killer (NK) cells, which respond quickly to an immunological threat. (nature.com)
  • Furthermore, other cells at the interface of the innate and the adaptive immune system (e.g cytokine-induced killer cells (CIK) or invariant natural killer T-cells (iNKT)) are important mediators in antitumor-, autoimmune-, and antimicrobial responses and tumor surveillance. (nature.com)
  • Regularly, anergy of T cells or other immune cells can be regularly reverted to anti-leukemic functionality. (nature.com)
  • Predicted epitopes were synthesized in the form of synthetic long peptides and tested in immune system sensitization assays involving unfractionated peripheral blood mononuclear cells (PBMC). (ndltd.org)
  • Hot spot" peptide Ag-specific T-cells preferentially recognized endogenous tumor derived MUC1, either in MUC1 expressing tumor cell killing assays (p=0.038, compared to non-peptide Ag-specific T-cells) or as MUC1 tumor lysate when pulsed onto restimulatory PBMC (p=0.022 and 0.025, for CD4+ and CD8+ T-cells, respectively, compared to T-cells directed against peptides from non-hot spot regions). (ndltd.org)
  • Background Peptide vaccines designed to stimulate melanoma-reactive CD4 + T cells can induce T cell and antibody (Ab) responses, associated with enhanced overall survival. (bmj.com)
  • Angiogenesis is the formation of new blood vessels from the existing vasculature, and it is significantly increased during tumor development with the aim to supply nutrients and oxygen that support the high rate proliferation of tumor cells. (researchsquare.com)
  • The result is the immunogenic cell death of tumor cells, accompanied by an auto-vaccination preventing the recurrence of cancer. (pipelinereview.com)
  • Sipuleucel-T consists of autologous peripheral blood mononuclear cells including antigen presenting cells (APCs). (asmepress.com)
  • The active components of Sipuleucel-T are autologous APCs and PAP-GM-CSF, in addition to T cells, B cells, natural killer cells, and other cells that specifically bind to PAP expressed in prostate cancer tissue to kill tumor cells. (asmepress.com)
  • NK cells contribute to cancer immune surveillance not only by their direct natural cytotoxicity which is triggered rapidly upon stimulation through germline-encoded cell surface receptors, but also by modulating T-cell mediated antitumor immune responses through maintaining the quality of dendritic cells and enhancing the presentation of tumor antigens. (frontiersin.org)
  • All of these products are designed to block the immune abrogating signals that enable cells to avoid immune destruction. (shu.edu)
  • We have discussed checkpoint blockade by PD-1, previously - PD-1 is a molecule expressed in the surface of T-cells , which when binding to PD-L1, causes the T-cell to down-regulate, that is, to no longer mount an anti-tumor immune response. (shu.edu)
  • Nivolumab is an antibody that binds to PD-1 and blocks it from interacting with PD-L1 (expressed on cancer cells and antigen presenting cells), which then prevents Cytotoxic T-cells from becoming down-regulated against the antigens expressed on the neighboring TCR (T-cell receptor) - see article . (shu.edu)
  • B, blockade of this pathway by anti-PD-1 antibodies prevents this downregulation, and allows T cells to maintain their antitumor functionality and ability to mediate tumor cell death. (shu.edu)
  • CTLA-4 (Yervoy - ipilimumab) and PD-1 (Opdivo - nivolumab) blockade accomplish similar objectives, though they act on different immune cells at different times in the immune response. (shu.edu)
  • B, PD-1 is mainly expressed on antigen-experienced memory T cells in peripheral tissues cells. (shu.edu)
  • Tumor cells use this regulatory mechanism to evade a tumor-directed T-cell response by upregulating the PD-1 ligands B7-H1 and B7-DC. (shu.edu)
  • Upon interaction with its ligand, galectin-9, Tim-3 induces a death signal in Th1 cells thereby contracting Th1 immune responses and preventing the immunopathology that would otherwise ensue. (shu.edu)
  • Tim-3 can therefore be classed along with other negative regulatory receptors such as CTLA-4 and PD-1, which are also expressed on T cells and serve to contract T cell responses. (shu.edu)
  • STARD14 was negatively associated with the infiltration of CD8+T cells, while positively with CCL28 and immune checkpoints, including CTLA4 as well as PD-L2. (medsci.org)
  • Her research involves direct reprogramming approaches, which function like a Trojan horse, enabling cancer cells to be targeted by the immune system. (lu.se)
  • By using direct reprogramming strategies, I could induce the expression of tumor antigens on the surface of cancer cells, making them visible to the immune system again. (lu.se)
  • We focused particularly on harnessing reprogramming, or direct cellular reprogramming, to induce antigen presentation in cancer cells. (lu.se)
  • when it comes to cancer they are critical as they present tumor antigens to the killer cells of the immune system and orchestrate the anti-tumor immune response. (lu.se)
  • Direct reprogramming strategies with cDC1-specific factors can induce antigen-presentation in cancer cells, making cancer cells visible to the immune system and easier to fight. (lu.se)
  • B cells are an important part of the immune cell infiltrate of tumors, and their contribution to tumor initiation, development, and immunosurveillance is complex with both pro- and anti-tumorigenic effects. (medjouel.com)
  • Recent studies implicate a fundamental role of B cells in shaping anti-tumor responses through several mechanisms. (medjouel.com)
  • While IgA + plasma cells regulate bacterial populations in the gut lumen in steady state, plasma cell-derived tumor-specific IgG1 antibodies mediate cell cytotoxicity and phagocytosis of tumor cells. (medjouel.com)
  • CRC patients show substantial alterations in their B cell compartment, with increasing numbers of IL-10 producing B cells in advanced tumors and metastases. (medjouel.com)
  • CRC patients with tumors highly infiltrated by CD20 + B cells display significantly improved survival, which suggests an anti-tumor role of B cells. (medjouel.com)
  • Antibody-independent mechanisms such as antigen presentation, cytokine production, direct cytotoxicity, and indirect effects through modulation of other immune cells have been demonstrated to be of great importance. (medjouel.com)
  • Thus, whether B cells promote or inhibit tumor growth depends on different variables, such as temporal and spatial settings, as well as on the composition of B cell subsets. (medjouel.com)
  • Therefore, a phenotypical and functional characterization of B cells in CRC tumor initiation and progression is of great interest with a possible therapeutic benefit. (medjouel.com)
  • We started investigating the role of B cells in the inflammatory phase, and at later time points of tumor development/progression in the well-established animal model of inflammation-induced CRC (AOM/DSS). (medjouel.com)
  • We could show that B cells exert an important role by using B cell-deficient mice (JHT mice), which were completely resistant to AOM/DSS-induced inflammation as well as CRC development. (medjouel.com)
  • HOOKIPA's approach is designed to focus the immune response against the target antigens and has demonstrated the ability to induce potent antigen-specific T cells responses and anti-tumor activity in preclinical and clinical settings. (decaturdailydemocrat.com)
  • Tumor Antigens Many tumor cells produce antigens, which may be released in the bloodstream or remain on the cell surface. (msdmanuals.com)
  • Despite the activity of effector cells, host immunoreactivity may fail to control tumor occurrence and growth. (msdmanuals.com)
  • The T cell is the primary cell responsible for direct recognition and killing of tumor cells. (msdmanuals.com)
  • T cells carry out immunologic surveillance, then proliferate and destroy newly transformed tumor cells after recognizing TAAs. (msdmanuals.com)
  • some cells require the presence of humoral antibodies directed against the tumor cells (antibody-dependent cellular cytotoxicity) to initiate the interactions that lead to the death of tumor cells. (msdmanuals.com)
  • In contrast, suppressor T cells inhibit the immune response against tumors. (msdmanuals.com)
  • Cytotoxic T lymphocytes (CTLs) recognize antigens on target cells and lyse these cells. (msdmanuals.com)
  • In contrast to CTLs, NK cells lack receptors for antigen detection but can still recognize normal cells infected with viruses and cancer cells. (msdmanuals.com)
  • Thus, the decreased level of class I molecule expression characteristic of many tumor cells may allow activation of NK cells and subsequent tumor lysis. (msdmanuals.com)
  • Natural killer T (NKT) cells are specialized CD1d-restricted T cells that recognize lipid antigens. (msdmanuals.com)
  • CD1d is a member of the CD1 (cluster of differentiation 1) group of glycoproteins on the surface of human antigen-presenting cells. (msdmanuals.com)
  • Macrophages can kill specific tumor cells when activated by a combination of factors, including lymphokines (soluble factors produced by T cells) and interferon. (msdmanuals.com)
  • Under certain circumstances, macrophages may present TAAs to T cells and stimulate tumor-specific immune response. (msdmanuals.com)
  • NK cells, among other cells, are key effector cells of the innate immune system and play a crucial role in the antiviral response. (cdc.gov)
  • Its SQZ TAC platform is designed to induce antigen-specific immune tolerance in vivo by utilizing a similar approach to the AAC platform. (stockhouse.com)
  • Effective cancer immuno- and virotherapies are hindered by a lack of identified tumor-associated antigens (TAAs), poor coverage of the antigenic repertoire expressed by tumors, and difficulties associated with targeting vectors to tumors in vivo , explains Dr. Vile, together with co-lead author Alan Melcher, at the U.K. Leeds Institute of Molecular Medicine and Cancer Research U.K. Clinical Center, and colleagues. (genengnews.com)
  • Nevertheless, building on the positive aspects of this approach, the researchers postulated that it may be possible to provide a broad antigenic repertoire for in vivo immune selection of relevant tumor-associated antigens by expressing a cDNA library of a normal tissue using a systemically delivered, immunogenic vector. (genengnews.com)
  • They chose VSV as the vector for delivering and expressing the antigens in vivo. (genengnews.com)
  • T cell responses were measured by interferon γ ELIspot assay ex vivo. (bmj.com)
  • Strong durable T cell responses to 6MHP were detected ex vivo in 0%, 29%, 67%, and 47% of participants on arms A-D, respectively. (bmj.com)
  • In vivo , CWO induced transcriptional changes in immune-related genes, resulting in cytotoxic T cell-dependent tumor regression. (biorxiv.org)
  • Blockade of CTLA-4 by antibodies has potentiated antitumor T-cell responses in both preclinical models and clinical trials. (aacrjournals.org)
  • By injecting the antibodies in a subcutaneous slow-release delivery formulation in the tumor area, we show that an eight-fold lower dose of antibody is as effective in inducing tumor eradication as systemic delivery. (aacrjournals.org)
  • Polyclonal antibody response was specific to VEGF, and showed no cross reactivity with other VEGF family members like VEGF-C and VEGF-D. Specific IgM, IgA and IgG antibodies detected in the serum of vaccinated patients were able to block the binding of VEGF to its receptors VEGFR1 and VEGFR2. (researchsquare.com)
  • These elicited antibodies impaired the high affinity interaction between VEGF and monoclonal antibody Bevacizumab, an antiangiogenic drug approved in combination with chemotherapy for the treatment of different tumors. (researchsquare.com)
  • CIGB-247 was immunogenic in a broader patient population, and induced Bevacizumab-like polyclonal antibodies, indicating that the VEGF-specific antibody response could have a potentially relevant clinical activity. (researchsquare.com)
  • Elicited polyclonal antibody response in addition to its cross-reactivity with human VEGF, have also demonstrated in rats and monkeys its capacity to impair the binding of Bevacizumab to VEGF [15, 16], indicating the presence of antibodies that block binding sites on VEGF which have shown to be clinically relevant. (researchsquare.com)
  • This single-chain TNFSF (tumor necrosis factor superfamily) technology is superior to other biologics targeting TNFSF pathways, such as agonistic antibodies. (apogenix.com)
  • HOOKIPA's replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. (decaturdailydemocrat.com)
  • In contrast to other cancers such as adenocarcinomas of the lung or melanoma, primary brain tumors like GB and low grade gliomas (LGG) are known as rather immunologically "cold" tumors, typically with low numbers of tumor-infiltrating lymphocytes (TILs) ( 4 ), and the mere amount of TILs is not associated with patient survival ( 5 ). (frontiersin.org)
  • RCC is an immunogenic tumor, and spontaneous regressions have been documented. (medscape.com)
  • We tested an essential-oil derivative, camphor white oil (CWO), for anti-tumor activity in a mouse model of keratinocyte-derived skin cancer. (biorxiv.org)
  • ER stress triggers Unfolded protein response (UPR) that protects against ER stress by decreasing unfolding of proteins. (helsinki.fi)
  • This intracellular clustering allows signaling proteins (4) inside the cell to be recruited (5), thereby initiating a response from the cell. (apogenix.com)
  • These antigens may be cell surface proteins or may be intracellular proteins (eg, TAAs) that are expressed on the surface in combination with class I major histocompatibility complex (MHC) molecules. (msdmanuals.com)
  • Collectively, these negative regulatory receptors are now commonly referred to as immune-checkpoint molecules. (shu.edu)
  • It is part of the Carinoembryonic Antigen (CEA) family of adhesion molecule receptors. (shu.edu)
  • A collaboration between Bristol-Myers Squibb and Kyowa Hakko Kirin to test a combination of Kyowa's Poteligeo (mogamulizumab), an anti-CCR4 antibody, and BMS' Opdivo (nivolumab) in a Phase I/II trial in advanced or metastatic solid tumors was announced. (shu.edu)
  • This review summarizes the use of high-voltage electrical pulses (HVEPs) in clinical oncology to treat solid tumors with irreversible electroporation (IRE) and electrochemotherapy (ECT). (rsna.org)
  • It unlocks novel dimensions by uncovering elusive cell populations and tumor heterogeneities for early detection, unraveling mechanisms of treatment resistance, tailoring therapies to individuals, and illuminating metastasis and cachexia pathways, thereby opening fresh avenues for preventive strategies. (frontiersin.org)
  • Although many immune components that participate in this process are known, its underlying mechanisms remain poorly defined. (nih.gov)
  • We use different preclinical mouse models of cancer to investigate the local administration of CTLA-4 blocking antibody and its effect on cancer progression and the antitumor T-cell response. (aacrjournals.org)
  • Escape from immune surveillance is thought to contribute to the development and progression of GB. (frontiersin.org)
  • In addition, recurrent tumors expressed genes associated with an epithelial-to-mesenchymal-type transition, and had lost, or at least reduced, expression of mouse homologs of the human RNAs encoding prostate-specific antigens in the ASEL. (genengnews.com)
  • the potent combination of high-voltage electrical pulses with immune cascade-enhancing drugs may offer a bridge between local-regional and systemic treatments in oncology. (rsna.org)
  • The company aims to use its mRNA technology to harness the immune system's power against cancer and infectious diseases. (biospace.com)
  • Libtayo, a monoclonal antibody, has previously been approved to treat metastatic cutaneous squamous cell carcinoma, advanced basal cell carcinoma, and patients with advanced non-small-cell lung cancer whose tumors have high PD-L1 expression. (biospace.com)
  • Cancer immunoediting, the process by which the immune system controls tumour outgrowth and shapes tumour immunogenicity, is comprised of three phases: elimination, equilibrium and escape. (nih.gov)
  • A central tenet of cancer immunoediting is that T-cell recognition of tumour antigens drives the immunological destruction or sculpting of a developing cancer. (nih.gov)
  • We also demonstrate that cancer immunoediting of d42m1 occurs via a T-cell-dependent immunoselection process that promotes outgrowth of pre-existing tumour cell clones lacking highly antigenic mutant spectrin-β2 and other potential strong antigens. (nih.gov)
  • BUFFALO, NY- November 17 , 2023 - A new research paper was published in Oncoscience ( Volume 10 ) on November 10, 2023, entitled, " An immunoinformatics assessment of the cancer testis antigen, DDX53, as a potential early esophageal cancer antigen . (biotechnews.com.au)
  • Chemical complementarity of the ESCA TCR CDR3s and the cancer testis antigen DDX53 represented a disease-free survival (DFS) distinction, whereby the upper fiftieth percentile complementarity group correlated with worse DFS. (biotechnews.com.au)
  • CIGB-247 is a cancer therapeutic vaccine that uses as antigen a variant of human vascular endothelial growth factor (VEGF) mixed with the bacterial-derived adjuvant VSSP. (researchsquare.com)
  • This report shows the characterization of the humoral response elicited after vaccination with 400 µg of antigen combined with 200 µg of VSSP in cancer patients representative of the Cuban real clinical practice setting. (researchsquare.com)
  • Prostate cancer is one of the most common malignant tumors of the urinary system. (asmepress.com)
  • Cancer vaccines use tumor cell-associated antigens to induce a specific anti-tumor immune response that is durable and robust. (asmepress.com)
  • Prostate acid phosphatase (PAP) is expressed in approximately 95% of prostate cancers and is mainly limited to prostate tissue, which is a target for prostate cancer tumor vaccine development. (asmepress.com)
  • Blocking a blocker allows the anti-tumor response (first wave) to proceed unabated, which in the context of cancer is the desired outcome. (shu.edu)
  • UV1 is a therapeutic cancer vaccine used to generate an immune response against the enzyme human telomerase (hTERT). (ultimovacs.com)
  • Lung cancer is the first leading diagnosed malignant tumor globally [ 1 ]. (medsci.org)
  • HB-300 uses the lymphocytic choriomeningitis virus (LCMV) and pichinde virus (PICV) as arenaviral backbones, with each expressing two well-defined antigens of prostate cancer, prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA). (decaturdailydemocrat.com)
  • Genetic studies of the families at high risk for developing renal cancer led to the cloning of genes whose alteration results in tumor formation. (medscape.com)
  • Computational immunogenomic approaches to predict response to cancer immunotherapies. (cdc.gov)
  • TL-532 also demonstrated its remarkable ability to overcome Immune Checkpoint Inhibitor (ICI) tumor-resistance, thus increasing the clinical landscape for ICI combination treatment. (pipelinereview.com)
  • We studied the relationship between KIR-human leukocyte antigen (HLA) combinations and the clinical outcomes of patients with Ebola virus disease (EVD). (cdc.gov)
  • Our findings highlight the importance of innate immune response against Ebola virus and show the association between KIRs and the clinical outcome of EVD. (cdc.gov)
  • Glioblastoma (GB) is the most frequent malignant primary brain tumor in adults, without any curative treatment options available at present. (frontiersin.org)
  • Daily topical treatment with CWO induced dramatic regression of pre-malignant skin tumors and a two-fold reduction in cutaneous squamous cell carcinomas. (biorxiv.org)
  • In oncology, it is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. (stockhouse.com)
  • Professor Binder is a renowned oncology clinician and researcher specializing in the analysis of immune-oncology treatments and their interaction with tumor tissues. (ultimovacs.com)
  • A, ligation of T-cell PD-1 by tumor B7-H1 results in the downregulation of T-cell effector functions that destroy tumor tissue. (shu.edu)
  • CTLA-4 and PD-1 modulate different aspects of the T-cell response: A, CTLA-4 is upregulated after antigen-specific activation of a naïve or memory T cell in lymphatic tissue, leading to decreased effector function (early activation phase). (shu.edu)
  • However, poor immunogenicity of tumor-associated antigens typically fails to induce an environment friendly immune response towards the tumor. (signetlabs.com)
  • ECT uses HVEPs to transiently increase membrane permeability, enhancing cellular cytotoxic drug uptake in tumors. (rsna.org)
  • Also, the trial data revealed that BNT111 enhanced pre-existing immune responses against the encoded melanoma-associated antigens. (biospace.com)
  • The Fast Track Designation underlines the potential of our FixVac platform to address current treatment challenges of pre-treated and immune checkpoint blocker experienced melanoma with limited standard of care therapy options left. (biospace.com)
  • Participants and methods An adaptive design based on toxicity and durable CD4+ T cell immune response (dRsp) was used to assign participants with resected stage IIA-IV melanoma to one of four study regimens. (bmj.com)
  • Three intravenous ASEL injections typically induced initial tumor regression, but with subsequent aggressive tumor recurrence. (genengnews.com)
  • This approach, they reasoned, might activate autoimmune and antitumor T cell responses, and dispense with the need for administration directly into normal tissues. (genengnews.com)
  • Together, these studies identify T cell-mediated tumor regression as the mechanism through which a plant-derived essential oil diminishes established tumor burden. (biorxiv.org)
  • SUMMARY BLURB Essential oil derived from the camphor tree acts by stimulating immune cell-dependent regression of skin tumors in a mouse model of cutaneous squamous cell carcinoma. (biorxiv.org)
  • The SQZ eAPC platform is the second-generation product candidate designed to generate tumor specific CD8+ T cell activation to drive the antitumor immune response. (stockhouse.com)
  • While this approach led to a broad repertoire of individually weak T cell responses against multiple TAAs that cumulatively resulted in strong selective pressure against immune escape, the need to inject the vectors into normal tissues often results in toxicity, they admit. (genengnews.com)
  • Overall, these data are consistent with the possibility that TCR-antigen interaction induces selective pressure that results in antigen loss, a process referred to as immuno-editing [ 16 - 18 ], and, eventually, tumor cell escape from an anti-tumor immune response. (biotechnews.com.au)
  • According to BioNTech, those antigens are expressed in more than 90% of cutaneous melanomas. (biospace.com)
  • cutaneous exposure to antigen in atopic dermatitis may enhance the development of asthma. (cdc.gov)
  • To address the problem of tumor recurrence, the researchers evaluated combinations of vaccination with differ-ent libraries. (genengnews.com)
  • Effective immune surveillance of patients with hematologic malignancies such as leukemia is mediated by cellular and noncellular arms of the innate and adaptive immune system. (nature.com)
  • The team cloned a cDNA library from normal human prostate, which they termed altered self antigen and epitope library (ASEL) into VSV, and systemically injected the antigen-expressing vector into normal experimental mice. (genengnews.com)
  • They then went on to test the virus-expressed human cDNA library in mice with established prostate tumors. (genengnews.com)
  • Nine intravenous injections of ASEL were sufficient to cure over 80% of mice with the prostate tumors, with no detectable autoim-mune prostatitis. (genengnews.com)
  • They first tried a second vaccination comprising virally expressed immune-escape epitope libraries (IEELs) constructed using cDNA from the recurrent tumors of ASEL-treated mice. (genengnews.com)
  • RESULTS: In tumor-implanted mice, the spinal MOR and KOR protein and mRNA expression was down-regulated when compared to that in sham-implanted mice (p (bvsalud.org)
  • Morphine, nalbuphine, or nalbuphine co-administration with morphine all can extend the paw withdrawal thermal latency (PWL) to radiant thermal stimulation in tumor-implanted mice (p (bvsalud.org)
  • Using class I prediction algorithms, we identify mutant spectrin-β2 as a potential rejection antigen of the d42m1 sarcoma and validate this prediction by conventional antigen expression cloning and detection. (nih.gov)
  • The possibility of disease-free survival increases after resection of primary tumor and excision of isolated metastasis. (medscape.com)
  • Perioperative durvalumab plus neoadjuvant chemotherapy was associated with significantly greater event-free survival and pathological complete response than neoadjuvant chemotherapy alone, with a safety profile that was consistent with the individual agents. (cdc.gov)
  • The immune modulation mediated by this pathway ensures protection of tissue from collateral damage during an inflammatory response. (shu.edu)
  • Researchers have developed a virus-based vaccine expressing a broad spectrum of undefined antigens from normal human prostate tissue that they claim completely eradicates established mouse prostate tumors in experimental animals. (genengnews.com)
  • Reporting in Nature Medicine , the team in the U.S. and U.K. that developed the approach says the vaccine can be delivered systemically without the need for tumor targeting, appears to have no side effects, and doesn't induce autoimmunity. (genengnews.com)
  • developed a therapeutic vaccine that uses as antigen a truncated form of human VEGF (aminoacids 26-104). (researchsquare.com)
  • This antigen sequence represents the complete Bevacizumab binding site and using RFASE as adjuvant, the vaccine (hVEGF 26-104 /RFASE) induces an immune response with VEGF neutralizing activity and anti-tumor effect [15]. (researchsquare.com)
  • To view a multidisciplinary tumor board case discussion, see Memorial Sloan Kettering e-Tumor Boards: Metastatic Clear Cell Renal Cell Carcinoma . (medscape.com)
  • We hypothesized that many tumor associated antigens (Ag) are readily susceptible to immune attack, but only in the context of identifying the tumor antigen epitopes that can reliably initiate an immune response, regardless of individual patient human leukocyte antigen (HLA) haplotype restrictions. (ndltd.org)
  • We hypothesized that adding toll-like receptor 3 agonist polyICLC to an incomplete Freund's adjuvant (IFA) would be safe and would support strong, durable CD4 + T cell and Ab responses. (bmj.com)
  • Unlike alternative ablative therapies, electroporation does not affect the structural integrity of surrounding tissue, thereby enabling tumors in the vicinity of vital structures to be treated. (rsna.org)
  • IRE uses HVEPs to cause cell death by inducing membrane disruption, and it is primarily used as a radical ablative therapy in the treatment of soft-tissue tumors in the liver, kidney, prostate, and pancreas. (rsna.org)
  • Chemotherapy is used only occasionally, in certain tumor types. (medscape.com)
  • The gut microbiota modulates immune processes both locally and systemically. (cdc.gov)
  • This administration method is associated with very low serum levels of antibody, which decreases the risk of treatment-induced side effects. (aacrjournals.org)
  • Irreversible electroporation is a predominantly nonthermal and adjacent structure-sparring ablation method that has been proven safe and efficient in the treatment of tumors in the liver, pancreas, and prostate. (rsna.org)
  • Increasingly, renal cell cancers are diagnosed at an earlier stage, and nephron-sparing surgery and thermal ablation are gaining acceptance as a treatment of choice for smaller tumors. (medscape.com)
  • This includes whether and how the immune system reacts to emerging tumours, whether antitumour immune responses are reactivated during treatment with immune-checkpoint inhibitors (ICIs), and whether unintended destructive immune pathologies accompany such treatment. (cdc.gov)
  • antigens, methods, and interpretation criteria for these assays differ from those for IGRAs approved previously by FDA. (cdc.gov)
  • However, responses vary significantly among eligible patients. (lu.se)